David Pozo Pérez-rekin lankidetzan egindako argitalpenak (10)

2013

  1. Preconditioning of microglia by α-synuclein strongly affects the response induced by toll-like receptor (TLR) stimulation

    PLoS ONE, Vol. 8, Núm. 11

2010

  1. Glial innate immunity generated by non-aggregated alpha-synuclein in mouse: Differences between wild-type and Parkinson's disease-linked mutants

    PLoS ONE, Vol. 5, Núm. 10

2009

  1. Chemical synthesis and characterization of silver-protected vasoactive intestinal peptide nanoparticles

    Nanomedicine, Vol. 4, Núm. 8, pp. 919-930

  2. Induction of alloantigen-specific human T regulatory cells by vasoactive intestinal peptide

    Journal of Immunology, Vol. 183, Núm. 7, pp. 4346-4359

  3. Toll-like receptor stimulation differentially regulates vasoactive intestinal peptide type 2 receptor in macrophages

    Journal of Cellular and Molecular Medicine, Vol. 13, Núm. 9 B, pp. 3209-3217

2007

  1. Tuning immune tolerance with vasoactive intestinal peptide: A new therapeutic approach for immune disorders

    Peptides, Vol. 28, Núm. 9, pp. 1833-1846

2006

  1. Protective role for plasmid DNA-mediated VIP gene transfer in non-obese diabetic mice

    Annals of the New York Academy of Sciences

  2. Therapeutic effect of vasoactive intestinal peptide on experimental autoimmune encephalomyelitis: Down-regulation of inflammatory and autoimmune responses

    American Journal of Pathology, Vol. 168, Núm. 4, pp. 1179-1188

  3. VIP prevents experimental multiple sclerosis by downregulating both inflammatory and autoimmune components of the disease

    Annals of the New York Academy of Sciences

2005

  1. Vasoactive intestinal peptide induces regulatory dendritic cells with therapeutic effects on autoimmune disorders

    Proceedings of the National Academy of Sciences of the United States of America, Vol. 102, Núm. 38, pp. 13562-13567